WINNIPEG, Manitoba--(BUSINESS WIRE)--Intelligent Hospital Systems (IH Systems) today announced the Australian Therapeutic Goods Administration (TGA), that nation’s equivalent of the U.S. Food and Drug Administration, has approved a workflow process in which one of Australia’s largest pharmaceutical compounders will use RIVA technology to produce patient chemotherapy doses. This is the first time the TGA has approved a drug compounding process that includes a fully automated IV compounding system in a Current Good Manufacturing Practice (cGMP) facility.
“We are excited to demonstrate the benefits of integrating IV automation technology in compounding chemotherapy medications,” said Dr. Niels Erik Hansen, president and CEO of IH Systems. “This is an important recognition that the processes, safety features and airflow design of RIVA meet the strict requirements for sterile compounding in a cGMP environment.”
Help employers find you! Check out all the jobs and post your resume.